Clinical Trials Browser

Carcinosarcoma, Glioma, Seminoma, Adenocarcinoma, Clear Cell, Carcinoma, Small Cell, Sex Cord-Gonadal Stromal Tumors, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT06406465 2026-03-18

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2 Recruiting

60 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

285 enrolled

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase 2 Recruiting

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Phase 2 Terminated

5 enrolled 9 charts

EndocrineNET

Recurrence, Neuroendocrine Tumors

NCT04969887 2026-02-27

MOST-CIRCUIT

Phase 2 Active not recruiting

240 enrolled

EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT04074135 2026-02-24

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Phase 2 Recruiting

740 enrolled

EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Clinical Trials

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

SUR-CAN

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

STARTRK-2

Entinostat Neuroendocrine (NE) Tumor

MOST-CIRCUIT

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors